Inhibikase Therapeutics (NYSE:IKT) Lowered to Neutral Rating by HC Wainwright

HC Wainwright cut shares of Inhibikase Therapeutics (NYSE:IKT - Free Report) from a buy rating to a neutral rating in a research note issued to investors on Wednesday, MarketBeat reports.

Separately, Jefferies Financial Group began coverage on shares of Inhibikase Therapeutics in a report on Friday, November 8th. They issued a "buy" rating and a $8.00 target price on the stock.

Inhibikase Therapeutics Stock Up 5.4 %

Shares of IKT stock traded up $0.12 on Wednesday, reaching $2.35. The stock had a trading volume of 122,438 shares, compared to its average volume of 192,038. The firm's 50-day moving average is $2.88 and its two-hundred day moving average is $2.17. The firm has a market capitalization of $163.00 million, a price-to-earnings ratio of -0.88 and a beta of 1.06. Inhibikase Therapeutics has a 12 month low of $1.12 and a 12 month high of $4.20.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of IKT. Stifel Financial Corp bought a new position in Inhibikase Therapeutics in the 4th quarter valued at about $43,000. Alpine Global Management LLC bought a new position in Inhibikase Therapeutics in the 4th quarter valued at about $48,000. Northern Trust Corp bought a new position in Inhibikase Therapeutics in the 4th quarter valued at about $208,000. Barclays PLC bought a new position in Inhibikase Therapeutics in the 4th quarter valued at about $273,000. Finally, Blair William & Co. IL raised its holdings in Inhibikase Therapeutics by 7.0% in the 4th quarter. Blair William & Co. IL now owns 134,953 shares of the company's stock valued at $439,000 after acquiring an additional 8,833 shares during the period. 3.81% of the stock is owned by institutional investors.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.